GSK aban­dons Ion­is' FDA-ready in­ot­ersen as new CEO sweeps out rare dis­ease ef­forts

Just three months af­ter Io­n­is spelled out pos­i­tive Phase III ef­fi­ca­cy da­ta on its top prospect in­ot­ersen, Glax­o­SmithK­line is sweep­ing their al­liance on the drug out the back door, along with rights to an­oth­er treat­ment they have rights to.

It’s a stun­ning 11th hour re­ver­sal for Io­n­is $IONS, which says it now plans to push for an FDA ap­proval of in­ot­ersen on its own this fall as it thinks through whether it will com­mer­cial­ize or co-com­mer­cial­ize in the US on its own.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters